Cargando…

P870: EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES

Detalles Bibliográficos
Autores principales:	Manier, Salomon, Lesokhin, Alexander, Mohty, Mohamad, Niesvizky, Ruben, Maisel, Christopher, Arnulf, Bertrand, Larson, Sarah M., Nina Varshavsky-Yanovsky, Asya, Leleu, Xavier, Karlin, Lionel, Vesole, David H., Bahlis, Nizar J, Fernandez de Larrea, Carlos, Raje, Noopur, Leip, Eric, Sullivan, Sharon T., Elmeliegy, Mohamed, Viqueira, Andrea, Nooka, Ajay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431166/ http://dx.doi.org/10.1097/01.HS9.0000970384.26808.c7

Ejemplares similares

P880: EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A SUBGROUP ANALYSIS FROM MAGNETISMM-3
por: Leleu, Xavier, et al.
Publicado: (2023)

P907: EFFICACY AND SAFETY OF ELRANATAMAB IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3
por: Touzeau, Cyrille, et al.
Publicado: (2023)

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
por: Lesokhin, Alexander M., et al.
Publicado: (2023)

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3
por: Lesokhin, A. M., et al.
Publicado: (2022)

S196: ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM MAGNETISMM-3
por: Mohty, Mohamad, et al.
Publicado: (2023)

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
por: Bahlis, Nizar J., et al.
Publicado: (2023)

P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2
por: Leleu, Xavier, et al.
Publicado: (2023)

P906: GENOMIC ANALYSIS TO IDENTIFY DETERMINANTS OF INHERENT RESPONSE AND RESISTANCE TO ELRANATAMAB IN MAGNETISMM-3 COHORT A
por: Rodríguez-Otero, Paula, et al.
Publicado: (2023)

PB2032: MAGNETISMM-9: AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Fonseca, R., et al.
Publicado: (2022)

P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
por: Dalovisio, A., et al.
Publicado: (2022)

PB2130: MAGNETISMM-6: A PHASE 3 STUDY OF ELRANATAMAB + DARATUMUMAB + LENALIDOMIDE VS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Grosicki, Sebastian, et al.
Publicado: (2023)

P908: IDENTIFICATION OF CYTOKINES ASSOCIATED WITH RESPONSE AND CYTOKINE RELEASE SYNDROME – ANALYSIS OF MAGNETISMM-3 COHORT A
por: Weisel, Katja, et al.
Publicado: (2023)

PB2131: MAGNETISMM-7: AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF ELRANATAMAB VERSUS LENALIDOMIDE IN POST-TRANSPLANT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Manteca, Maria Victoria Mateos, et al.
Publicado: (2023)

P957: AN INDIRECT COMPARISON OF ELRANATAMAB’S (ELRA) OBJECTIVE RESPONSE RATE (ORR) FROM MAGNETISMM-3 (MM-3) VERSUS REAL-WORLD EXTERNAL CONTROL ARMS IN TRIPLE-CLASS REFRACTORY (TCR) MULTIPLE MYELOMA (MM)
por: Costa, Luciano, et al.
Publicado: (2023)

P940: AN OUTPATIENT MODEL FOR TECLISTAMAB STEP-UP DOSING ADMINISTRATION – INITIAL EXPERIENCES AT FOX CHASE CANCER CENTER BMT PROGRAM.
por: Nina Varshavsky-Yanovsky, Asya, et al.
Publicado: (2023)

A phase 1b study of once‐weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma
por: Alsina, Melissa, et al.
Publicado: (2020)

Elrexfio™ (elranatamab-bcmm): The game-changer in treatment of multiple myeloma
por: Rais, Taruba, et al.
Publicado: (2023)

Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma
por: Frigault, Matthew J., et al.
Publicado: (2022)

Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case
por: Mutlu, Yasa Gul, et al.
Publicado: (2023)

Report about fire in building 870 / BA 3
Publicado: (1997)

Report about fire in building 870 / BA 3
Publicado: (1997)

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
por: Cho, Shih-Feng, et al.
Publicado: (2018)

sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
por: Seipel, Katja, et al.
Publicado: (2022)

Successful Inhibition of Tumor Development by Specific Class-3 Semaphorins Is Associated with Expression of Appropriate Semaphorin Receptors by Tumor Cells
por: Kigel, Boaz, et al.
Publicado: (2008)

Targeting nanomedicines in the treatment of Crohn’s disease: focus on certolizumab pegol (CDP870)
por: Dinesen, Lotte, et al.
Publicado: (2007)

The complete genome sequence of the nitrile biocatalyst Rhodocccus rhodochrous ATCC BAA-870
por: Frederick, Joni, et al.
Publicado: (2020)

870. Mycobacterium chimaera Outbreak: Infection Control and Clinical Experiences in Edmonton, Alberta
por: Kula, Brittany E, et al.
Publicado: (2020)

BCMA-targeted immunotherapy for multiple myeloma
por: Yu, Bo, et al.
Publicado: (2020)

P962: COMMERCIAL TECLISTAMAB IN ANTI-BCMA THERAPY EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS: THE MSKCC EXPERIENCE.
por: Firestone, Ross, et al.
Publicado: (2023)

Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report
por: Li, Dan, et al.
Publicado: (2022)

Cyclin D1 A870G polymorphism and the risk of colorectal cancer and adenoma
por: Schernhammer, E S, et al.
Publicado: (2006)

Substrate Profiling of the Cobalt Nitrile Hydratase from Rhodococcus rhodochrous ATCC BAA 870
por: Mashweu, Adelaide R., et al.
Publicado: (2020)

POS-870 NGAL and microalbuminuria as AKi biomarkers in COVID-19 hospitalized patients with pneumonia
por: Rizo Topete MD, L., et al.
Publicado: (2022)

Eccentricity-paced geomagnetic field and monsoon rainfall variations over the last 870 kyr
por: Zhou, Weijian, et al.
Publicado: (2023)

Anti-BCMA novel therapies for multiple myeloma
por: Sammartano, Vincenzo, et al.
Publicado: (2023)

Teclistamab impairs detection of BCMA CAR-T cells
por: Glatte, Bettina, et al.
Publicado: (2023)

P26 LANDSCAPE OF RECURRENT CYTOGENETIC ABNORMALITIES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AS DETECTED BY CHROMOSOME MICROARRAY ANALYSIS (CMA)
por: Varshavsky Yanovsky, A., et al.
Publicado: (2023)

P879: LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: Sidana, Surbhi, et al.
Publicado: (2023)

Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
por: Yee, Andrew J, et al.
Publicado: (2012)

Panobinostat and Multiple Myeloma in 2018
por: Yee, Andrew J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3k8ub5gql5aokqdveme5sl499q